Mayienne Bakkers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mayienne Bakkers has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Catharina G. Faber
Department of Neurology Maastricht University Medical Centre P.O. Box 5800 6202 AZ Maastricht The Netherlands
3 shared publications- Catharina Gerritdina Faber
Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
3 shared publications - Giuseppe Lauria
3rd Neurology Unit and Motor Neuron Disease Centre Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
3 shared publications Ingemar S.J. Merkies
Department of Neurology Spaarne Hospital Hoofddorp The Netherlands
3 shared publicationsJanneke G.J. Hoeijmakers
Department of Neurology Maastricht University Medical Centre P.O. Box 5800 6202 AZ Maastricht The Netherlands
3 shared publicationsJos P.H. Reulen
Department of Clinical Neurophysiology Maastricht University Medical Centre Maastricht The Netherlands
2 shared publications
Latest Publications
- 31 March 2015
- Published by Wiley in Muscle & Nerve
- Vol. 51 (5) , 743-749
Contact heat evoked potentials: Normal values and use in small‐fiber neuropathy
Introduction: Contact heat evoked potentials (CHEPs) may be an objective, non‐invasive diagnostic tool in small‐fiber neuropathy (SFN). This study establishes normal CHEP values and examines their applicability in SFN patients. Methods: Standardized CHEPs were administered at the wrist and ankle. The N2 and P2 latencies and N2–P2 peak–peak amplitude were recorded by electroencephalography. We examined healthy subjects (n = 97), stratified by age and gender, and SFN patients with abnormal intraepidermal nerve fiber density (n = 42). CHEP reproducibility and interobserver values were also investigated. Results: CHEP normative values were determined. There was a 9–16% increase in latency per centimeter of height with increasing age. Amplitudes were higher in women than men, and decreased (17–71%) with aging. Test‐retest reproducibility and interobserver values were >0.61 and >0.96, respectively. CHEPs were abnormal in 73.8% of the patients. Conclusion: In this study we have established normal values, reliability, and clinical applicability of CHEPs in SFN. Muscle Nerve, 2015 Muscle Nerve 51:743–749, 2015
- 31 March 2015
- Published by Wiley in Muscle & Nerve
- Vol. 51 (5) , 743-749
Contact heat evoked potentials: Normal values and use in small‐fiber neuropathy
Introduction: Contact heat evoked potentials (CHEPs) may be an objective, non‐invasive diagnostic tool in small‐fiber neuropathy (SFN). This study establishes normal CHEP values and examines their applicability in SFN patients. Methods: Standardized CHEPs were administered at the wrist and ankle. The N2 and P2 latencies and N2–P2 peak–peak amplitude were recorded by electroencephalography. We examined healthy subjects (n = 97), stratified by age and gender, and SFN patients with abnormal intraepidermal nerve fiber density (n = 42). CHEP reproducibility and interobserver values were also investigated. Results: CHEP normative values were determined. There was a 9–16% increase in latency per centimeter of height with increasing age. Amplitudes were higher in women than men, and decreased (17–71%) with aging. Test‐retest reproducibility and interobserver values were >0.61 and >0.96, respectively. CHEPs were abnormal in 73.8% of the patients. Conclusion: In this study we have established normal values, reliability, and clinical applicability of CHEPs in SFN. Muscle Nerve, 2015 Muscle Nerve 51:743–749, 2015
- 7 October 2014
- Published by Wiley in Muscle & Nerve
- Vol. 51 (6) , 870-876
Optimizing temperature threshold testing in small-fiber neuropathy
Introduction: We examined optimization of a temperature threshold testing (TTT) protocol for patients with suspected small-fiber neuropathy (SFN) to lessen the burden for both patients and technicians, without sacrificing accuracy. Methods: Data from 81 patients with SFN (skin biopsy and TTT abnormal) and 81 without SFN (skin biopsy and TTT normal) were used. Warm, cold, and heat pain sensation thresholds were determined bilaterally on the thenar eminence and foot dorsum by methods of limits and levels. Diagnostic accuracy was determined for various sensory modality combinations through comparative corresponding area under the receiver-operator characteristic curves. Results: Assessment of warm and cold thresholds in all extremities by the method of levels showed the best discriminatory ability (area under the curve 0.95, sensitivity 84.2%, specificity 93.8%). Conclusions: These assessments are suggested for TTT examination in possible SFN patients. By applying this combination, the time needed for TTT can be reduced, maintaining diagnostic accuracy. Muscle Nerve 51: 870–876, 2015
- 7 October 2014
- Published by Wiley in Muscle & Nerve
- Vol. 51 (6) , 870-876
Optimizing temperature threshold testing in small-fiber neuropathy
Introduction: We examined optimization of a temperature threshold testing (TTT) protocol for patients with suspected small-fiber neuropathy (SFN) to lessen the burden for both patients and technicians, without sacrificing accuracy. Methods: Data from 81 patients with SFN (skin biopsy and TTT abnormal) and 81 without SFN (skin biopsy and TTT normal) were used. Warm, cold, and heat pain sensation thresholds were determined bilaterally on the thenar eminence and foot dorsum by methods of limits and levels. Diagnostic accuracy was determined for various sensory modality combinations through comparative corresponding area under the receiver-operator characteristic curves. Results: Assessment of warm and cold thresholds in all extremities by the method of levels showed the best discriminatory ability (area under the curve 0.95, sensitivity 84.2%, specificity 93.8%). Conclusions: These assessments are suggested for TTT examination in possible SFN patients. By applying this combination, the time needed for TTT can be reduced, maintaining diagnostic accuracy. Muscle Nerve 51: 870–876, 2015
- 28 May 2013
- Published by Wiley in Muscle & Nerve
- Vol. 49 (3) , 329-336
Small fibers, large impact: Quality of life in small‐fiber neuropathy
Introduction: The impact of small‐fiber neuropathy (SFN) on patients' quality of life (QOL) has not been studied extensively. Our aim was to determine the impact of SFN on QOL and examine possible determinants. Methods: We examined a total of 265 patients diagnosed with SFN. The SFN Symptoms Inventory Questionnaire (SFN‐SIQ), the pain Visual Analog Scale (VAS), and the generic SF‐36 Health Survey were assessed. Regression studies were undertaken to evaluate determinants of functioning. Results: SFN patients demonstrated a severe overall reduction in QOL. The biggest deficits were in Role Functioning–Physical, Body Pain, and Physical Component Summary (PCS) scores. VAS scores, changed sweating pattern, dry mouth, and age were the strongest predictors for PCS, explaining 32% of the QOL decrease. Conclusions: SFN leads to a reduction in overall QOL. The presence of pain and some autonomic symptoms explained only a small portion of the findings. Muscle Nerve 49:329–336, 2014
- 28 May 2013
- Published by Wiley in Muscle & Nerve
- Vol. 49 (3) , 329-336
Small fibers, large impact: Quality of life in small‐fiber neuropathy
Introduction: The impact of small‐fiber neuropathy (SFN) on patients' quality of life (QOL) has not been studied extensively. Our aim was to determine the impact of SFN on QOL and examine possible determinants. Methods: We examined a total of 265 patients diagnosed with SFN. The SFN Symptoms Inventory Questionnaire (SFN‐SIQ), the pain Visual Analog Scale (VAS), and the generic SF‐36 Health Survey were assessed. Regression studies were undertaken to evaluate determinants of functioning. Results: SFN patients demonstrated a severe overall reduction in QOL. The biggest deficits were in Role Functioning–Physical, Body Pain, and Physical Component Summary (PCS) scores. VAS scores, changed sweating pattern, dry mouth, and age were the strongest predictors for PCS, explaining 32% of the QOL decrease. Conclusions: SFN leads to a reduction in overall QOL. The presence of pain and some autonomic symptoms explained only a small portion of the findings. Muscle Nerve 49:329–336, 2014
- 1 January 2012
- Vol. 156 (7) , A4224
[Small fibre neuropathy: knowledge is power].
Small fibre neuropathy is a neuropathy of the small non-myelinated C-fibres and myelinated Aδ-fibres. Clinically, an isolated small fibre neuropathy is distinguished by sensory and autonomic symptoms, with practically no abnormalities on neurological examination other than possible distorted pain and temperature sensation. Specific diagnostic tests for small fibre neuropathy are skin biopsy, including a count of the intra-epidermal small nerve fibres that cross the basal membrane, and quantitative sensory and autonomic testing. Diabetes mellitus is the most frequent underlying cause of small fibre neuropathy. Other causes can be classified into the following categories: toxic (e.g. alcohol), metabolic, immune-mediated, infectious and hereditary. Recently, in a substantial proportion (29%) of a group of patients with idiopathic small fibre neuropathy, a SCN9A gene mutation was demonstrated, which leads to hyperexcitability of the dorsal root ganglion neurons. Treatment of small fibre neuropathy consists of symptomatic pain relief and, if possible, treatment of the underlying cause of the condition.
- 1 January 2012
- Vol. 156 (7) , A4224
[Small fibre neuropathy: knowledge is power].
Small fibre neuropathy is a neuropathy of the small non-myelinated C-fibres and myelinated Aδ-fibres. Clinically, an isolated small fibre neuropathy is distinguished by sensory and autonomic symptoms, with practically no abnormalities on neurological examination other than possible distorted pain and temperature sensation. Specific diagnostic tests for small fibre neuropathy are skin biopsy, including a count of the intra-epidermal small nerve fibres that cross the basal membrane, and quantitative sensory and autonomic testing. Diabetes mellitus is the most frequent underlying cause of small fibre neuropathy. Other causes can be classified into the following categories: toxic (e.g. alcohol), metabolic, immune-mediated, infectious and hereditary. Recently, in a substantial proportion (29%) of a group of patients with idiopathic small fibre neuropathy, a SCN9A gene mutation was demonstrated, which leads to hyperexcitability of the dorsal root ganglion neurons. Treatment of small fibre neuropathy consists of symptomatic pain relief and, if possible, treatment of the underlying cause of the condition.
- Open Access
- 20 July 2010
- Published by Springer Nature in Journal of Neurology
- Vol. 257 (12) , 2086-2090
Pain and autonomic dysfunction in patients with sarcoidosis and small fibre neuropathy
Small fibre neuropathy (SFN) has been demonstrated in sarcoidosis. However, a systematic analysis of neuropathic pain and autonomic symptoms, key features of SFN, has not been performed. Clinimetric evaluation of pain and autonomic symptoms using the neuropathic pain scale (NPS) and the modified Composite Autonomic Symptoms Scale (mCOMPASS) was used in sarcoidosis patients for this study. A total of 91 sarcoidosis patients (n = 23 without SFN symptoms, n = 43 with SFN symptoms but normal intraepidermal nerve fibre density (IENFD), n = 25 with SFN symptoms and reduced IENFD) were examined. NPS and mCOMPASS were assessed twice (reliability studies). Severity of pain was compared between the subgroups. Correlation between NPS and a visual analogue pain scale (VAS) was assessed (validity studies). Healthy controls (n = 105) completed the mCOMPASS for comparison with patients’ scores. Patients with sarcoidosis, SFN complaints, and reduced IENFD demonstrated more severe pain scores on the NPS. The mCOMPASS differentiated between subjects with and without SFN symptoms. A significant correlation was obtained between the NPS and VAS, indicating good construct validity. Good reliability values were obtained for all scales. The use of the NPS to evaluate SFN symptoms is suggested, as it shows differences between patients with SFN symptoms with normal or reduced IENFD values. The mCOMPASS might be used to select patients for further testing.
- 20 July 2010
- Published by Springer Nature in Journal of Neurology
- Vol. 257 (12) , 2086-2090
Open AccessPain and autonomic dysfunction in patients with sarcoidosis and small fibre neuropathy
Small fibre neuropathy (SFN) has been demonstrated in sarcoidosis. However, a systematic analysis of neuropathic pain and autonomic symptoms, key features of SFN, has not been performed. Clinimetric evaluation of pain and autonomic symptoms using the neuropathic pain scale (NPS) and the modified Composite Autonomic Symptoms Scale (mCOMPASS) was used in sarcoidosis patients for this study. A total of 91 sarcoidosis patients (n = 23 without SFN symptoms, n = 43 with SFN symptoms but normal intraepidermal nerve fibre density (IENFD), n = 25 with SFN symptoms and reduced IENFD) were examined. NPS and mCOMPASS were assessed twice (reliability studies). Severity of pain was compared between the subgroups. Correlation between NPS and a visual analogue pain scale (VAS) was assessed (validity studies). Healthy controls (n = 105) completed the mCOMPASS for comparison with patients’ scores. Patients with sarcoidosis, SFN complaints, and reduced IENFD demonstrated more severe pain scores on the NPS. The mCOMPASS differentiated between subjects with and without SFN symptoms. A significant correlation was obtained between the NPS and VAS, indicating good construct validity. Good reliability values were obtained for all scales. The use of the NPS to evaluate SFN symptoms is suggested, as it shows differences between patients with SFN symptoms with normal or reduced IENFD values. The mCOMPASS might be used to select patients for further testing.
- 6 October 2009
- Published by Wolters Kluwer Health in Neurology
- Vol. 73 (14) , 1142-1148
Intraepidermal nerve fiber density and its application in sarcoidosis
Background: Intraepidermal nerve fiber density (IENFD) is considered a good diagnostic tool for small fiber neuropathy (SFN). Objectives: To assess stratified normative values for IENFD and determine the reliability and validity of IENFD in sarcoidosis. Methods: IENFD was assessed in 188 healthy volunteers and 72 patients with sarcoidosis (n = 58 with SFN symptoms, n = 14 without SFN symptoms). Healthy controls were stratified (for age and sex), resulting in 6 age groups (20–29, 30–39, … up to ≥70 years) containing at least 15 men and 15 women. A skin biopsy was taken in each participant 10 cm above the lateral malleolus and analyzed in accordance with the international guidelines using bright-field microscopy. Interobserver/intraobserver reliability of IENFD was examined. In the patients, a symptoms inventory questionnaire (SIQ; assessing SFN symptoms) and the Vickrey Peripheral Neuropathy Quality-of-Life Instrument-97 (PNQoL-97) were assessed to examine the discriminative ability of normative IENFD values. Results: There was a significant age-dependent decrease of IENFD values in healthy controls, with lower densities in men compared with women. Good interobserver/intraobserver reliability scores were obtained (κ values ≥0.90). A total of 21 patients with sarcoidosis had a reduced IENFD score (<5th percentile; 19 [32.8%] in patients with SFN symptoms, 2 [14.3%] in patients without SFN symptoms). The validity of the normative IENFD values was demonstrated by distinguishing between the SIQ scores and various PNQoL-97 values for the different patient groups. Conclusion: This study provides clinically applicable distal intraepidermal nerve fiber density normative values, showing age- and sex-related differences.
- 6 October 2009
- Published by Wolters Kluwer Health in Neurology
- Vol. 73 (14) , 1142-1148
Intraepidermal nerve fiber density and its application in sarcoidosis
Background: Intraepidermal nerve fiber density (IENFD) is considered a good diagnostic tool for small fiber neuropathy (SFN). Objectives: To assess stratified normative values for IENFD and determine the reliability and validity of IENFD in sarcoidosis. Methods: IENFD was assessed in 188 healthy volunteers and 72 patients with sarcoidosis (n = 58 with SFN symptoms, n = 14 without SFN symptoms). Healthy controls were stratified (for age and sex), resulting in 6 age groups (20–29, 30–39, … up to ≥70 years) containing at least 15 men and 15 women. A skin biopsy was taken in each participant 10 cm above the lateral malleolus and analyzed in accordance with the international guidelines using bright-field microscopy. Interobserver/intraobserver reliability of IENFD was examined. In the patients, a symptoms inventory questionnaire (SIQ; assessing SFN symptoms) and the Vickrey Peripheral Neuropathy Quality-of-Life Instrument-97 (PNQoL-97) were assessed to examine the discriminative ability of normative IENFD values. Results: There was a significant age-dependent decrease of IENFD values in healthy controls, with lower densities in men compared with women. Good interobserver/intraobserver reliability scores were obtained (κ values ≥0.90). A total of 21 patients with sarcoidosis had a reduced IENFD score (<5th percentile; 19 [32.8%] in patients with SFN symptoms, 2 [14.3%] in patients without SFN symptoms). The validity of the normative IENFD values was demonstrated by distinguishing between the SIQ scores and various PNQoL-97 values for the different patient groups. Conclusion: This study provides clinically applicable distal intraepidermal nerve fiber density normative values, showing age- and sex-related differences.